Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerwin Huls

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
Blood|November 16, 2017
Decitabine enhances targeting of AML cells by CD34<sup>+</sup> progenitor-derived NK cells in NOD/SCID/IL2Rg<sup>null</sup> miceJeannette Cany, Mieke W H Roeven, Janneke S Hoogstad-van Evert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2016
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell ResponsesMarjan Cruijsen, Willemijn Hobo, Walter J F M van der Velden, et al.
Transplantation and Cellular Therapy|March 30, 2021
Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional ChemotherapyJacobien R Hilberink, Linde M Morsink, Walter J F M van der Velden, et al.
Blood|June 22, 2011
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TrialEvelien Kneppers, Bronno van der Holt, Marie-Jose Kersten, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use programEvelien Kneppers, Henk M Lokhorst, Corien M Eeltink, et al.
Bone Marrow Transplantation|April 7, 2021
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantationMarjan Cruijsen, Jacobien R Hilberink, Walter J F M van der Velden, et al.
Rheumatology (Oxford, England)|August 26, 2023
Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controlsJonas B Salzbrunn, Isabelle A van Zeventer, Aniek O de Graaf, et al.
Hemasphere|January 14, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacyIda Vänttinen, Joseph Saad, Tanja Ruokoranta, et al.
American Journal of Hematology|October 21, 2024
Clonal hematopoiesis and myeloid skewing in older population-based individualsMaaike G J M van Bergen, Priscilla Kamphuis, Aniek O de Graaf, et al.
Blood Cancer Journal|March 28, 2024
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trialNiek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Blood|November 16, 2017
Decitabine enhances targeting of AML cells by CD34<sup>+</sup> progenitor-derived NK cells in NOD/SCID/IL2Rg<sup>null</sup> miceJeannette Cany, Mieke W H Roeven, Janneke S Hoogstad-van Evert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2016
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell ResponsesMarjan Cruijsen, Willemijn Hobo, Walter J F M van der Velden, et al.
Transplantation and Cellular Therapy|March 30, 2021
Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional ChemotherapyJacobien R Hilberink, Linde M Morsink, Walter J F M van der Velden, et al.
Blood|June 22, 2011
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TrialEvelien Kneppers, Bronno van der Holt, Marie-Jose Kersten, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use programEvelien Kneppers, Henk M Lokhorst, Corien M Eeltink, et al.
Bone Marrow Transplantation|April 7, 2021
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantationMarjan Cruijsen, Jacobien R Hilberink, Walter J F M van der Velden, et al.
Rheumatology (Oxford, England)|August 26, 2023
Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controlsJonas B Salzbrunn, Isabelle A van Zeventer, Aniek O de Graaf, et al.
Hemasphere|January 14, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacyIda Vänttinen, Joseph Saad, Tanja Ruokoranta, et al.
American Journal of Hematology|October 21, 2024
Clonal hematopoiesis and myeloid skewing in older population-based individualsMaaike G J M van Bergen, Priscilla Kamphuis, Aniek O de Graaf, et al.
Blood Cancer Journal|March 28, 2024
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trialNiek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, et al.
Pageof 17